Adjunctive benefits of systemic etoricoxib in non-surgical treatment of aggressive periodontitis: short-term evaluation.
BACKGROUND
This pilot study assessed the effect of short-duration treatment with etoricoxib as adjuvant therapy to scaling and root planing (SRP) on the clinical and radiographic parameters and prostaglandin E(2) (PGE(2)) levels in aggressive periodontitis.


METHODS
Subjects were randomly allocated to test or control treatment (n = 10 in each group) and submitted to SRP and treatment with etoricoxib, 120 mg/day, or placebo for 7 days. Probing depth, clinical attachment level (CAL), gingival recession, visible plaque index, bleeding on probing, linear distance (LD) from the cemento-enamel junction to the alveolar crest, and analysis of the gray levels were recorded before and 1 month after the therapies. The prostaglandin E(2) (PGE(2)) level in the gingival crevicular fluid (GCF) was measured by radioimmunoassay at the beginning of the study and 7 and 30 days after treatment.


RESULTS
No significant difference in the clinical parameters was observed between the groups at the end of the experimental period, although both groups presented significant improvement in all variables examined. There was a decrease in CAL from 5.54 +/- 0.47 mm to 3.59 +/- 0.53 mm in the test group and from 5.92 +/- 1.10 mm to 3.69 +/- 0.80 mm in the control group. A significant reduction in PGE(2) was found after 7 days of treatment. LD differed between the groups.


CONCLUSIONS
Etoricoxib did not promote additional improvement in the clinical parameters; however, it produced an initial reduction in the PGE(2) levels in the GCF, which could be related to the discrete improvement in the bone condition.
Azoubel
Maria Cecília F
MC
Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.
Sarmento
Viviane A
VA
Cangussú
Virna
V
Azoubel
Eduardo
E
Bittencourt
Sandro
S
Cunha
Fernando Q
FQ
Ribeiro
Ronaldo A
RA
Brito
Gerly Anne C
GA
D000293:Adolescent; D000328:Adult; D016301:Alveolar Bone Loss / Q000188:drug therapy / Q000628:therapy; D003131:Combined Modality Therapy; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D012534:Dental Scaling; D015232:Dinoprostone / Q000032:analysis; D004311:Double-Blind Method; D000077613:Etoricoxib; D005260:Female; D005500:Follow-Up Studies; D005883:Gingival Crevicular Fluid / Q000737:chemistry; D005884:Gingival Hemorrhage / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D008297:Male; D017622:Periodontal Attachment Loss / Q000188:drug therapy / Q000628:therapy; D010514:Periodontal Pocket / Q000188:drug therapy / Q000628:therapy; D010518:Periodontitis / Q000188:drug therapy* / Q000628:therapy; D010865:Pilot Projects; D010919:Placebos; D011725:Pyridines / Q000627:therapeutic use*; D016745:Root Planing; D013450:Sulfones / Q000627:therapeutic use*; D019237:Tooth Cervix / Q000473:pathology
D016861:Cyclooxygenase Inhibitors; D010919:Placebos; D011725:Pyridines; D013450:Sulfones; D015232:Dinoprostone; D000077613:Etoricoxib